Immunocore Holdings plc (IMCR)

Market Cap	2.46B
Revenue (ttm)	173.18M
Net Income (ttm)	-49.67M
Shares Out	49.93M
EPS (ttm)	-1.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	187,651
Open	48.87
Previous Close	47.52
Day's Range	48.87 - 50.90
52-Week Range	25.01 - 69.06
Beta	0.61
Analysts	Buy
Price Target	82.72 (+67.5%)
Earnings Date	May 10, 2023

About IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 324
• Stock Exchange: NASDAQ
• Ticker Symbol: IMCR

Financial Performance

In 2022, IMCR's revenue was 143.74 million, an increase of 441.99% compared to the previous year's 26.52 million. Losses were -41.22 million, -68.66% less than in 2021.

Financial numbers in GBP

Analyst Forecast

According to 16 analysts, the average rating for IMCR stock is "Buy." The 12-month stock price forecast is $82.72, which is an increase of 67.50% from the latest price.

Price Target

$82.72

(67.50% upside)

Analyst Consensus: Buy